The AUA partnered with ASTRO on the guideline and it was endorsed by the SUO.
James A. Eastham, MD, explains the updates that were made in the recently released 2022 clinical practice guideline for the management of clinically localized prostate cancer from the American Urological Association (AUA) and the American Society for Radiation Oncology (ASTRO). The guideline was shared during the 2022 AUA Annual Meeting and published in the Journal of Urology (doi: 10.1097/JU.0000000000002757). The guideline was also endorsed by the Society of Urologic Oncology (SUO).
Eastham is chair of guideline development panel and chief of Urology Services at Memorial Sloan Kettering Cancer Center.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.